Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.53 |
| ▸ | MTOR | P42345 | 8/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | S100A9 | P06702 | 3/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15556197 | 0.88 | MTOR (0.55) | PIK3CAMTORPIK3CGPIK3CDPIK3R1 | |
| SCHEMBL25390717 | 0.86 | PIK3CA (0.42) | PIK3CAMTORPIK3CGPIK3CDPIK3R1 | |
| SCHEMBL30572690 | 0.86 | PIK3CA (0.42) | PIK3CAMTORPIK3CGPIK3CDPIK3R1 | |
| SCHEMBL22447636 | 0.85 | PIK3CG (0.46) | PIK3CAMTORPIK3CGS100A9PIK3CD | |
| SCHEMBL22447721 | 0.84 | GLO1 (0.46) | PIK3CAMTORPIK3CGS100A9PIK3CD | |
| SCHEMBL358926 | 0.83 | PIK3CG (0.63) | PIK3CAMTORPIK3CGS100A9PIK3CD | |
| SCHEMBL16551868 | 0.82 | PIK3CA (0.55) | PIK3CAMTORPIK3CGMEN1POLB | |
| SCHEMBL28549695 | 0.82 | PIK3CG (0.50) | PIK3CAMTORPIK3CGS100A9PIK3CD | |
| SCHEMBL30333387 | 0.81 | PIK3CA (0.45) | PIK3CAMTORPIK3CGPIK3CDPIK3R1 | |
| SCHEMBL22447546 | 0.81 | CCR4 (0.59) | PIK3CAMTORPIK3CGS100A9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168118-A1 | N-(5-QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | SECOND MILITARY MEDICAL UNIVERSITY, PLA (CN) | 2016-06-16 | — | — | US | disclosed |
| US-20160168118-A1 | N-(5-QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | SECOND MILITARY MEDICAL UNIVERSITY, PLA (CN) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168118-A1 | N-(5-QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | GLS2, CYP3A5, HCCS | PIK3CA 532/4885MTOR 1636/4885HDAC1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.